Brief: Arcus Biosciences Announces Clinical Supply Agreement With Aveo Oncology
22/07/2026 22:39
BRIEF-Arcus Biosciences Announces Clinical Supply Agreement With Aveo Oncology July 22 (Reuters) - Arcus Biosciences Inc RCUS.N:
ARCUS BIOSCIENCES ANNOUNCES CLINICAL SUPPLY AGREEMENT WITH AVEO ONCOLOGY TO EVALUATE CASDATIFAN IN COMBINATION WITH TIVOZANIB FOR ADVANCED KIDNEY CANCER PATIENTS
ARCUS BIOSCIENCES - ENROLLMENT FOR NEW ARC-20 COHORT EXPECTED TO BEGIN IN Q4 2026
ARCUS BIOSCIENCES - AVEO TO SUPPLY TIVOZANIB; ARCUS TO SPONSOR STUDY; EACH RETAINS RIGHTS TO COMPOUNDS
Source text: ID:nBw8Y6Z5ya
Further company coverage: RCUS.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arcus Biosciences
See all newsU.S. STOCKS ON THE MOVE-Quest Diagnostics, Tractor Supply, Dutch Bros
U.S. STOCKS ON THE MOVE-CME, Lockheed Martin, Valero Energy
Arcus Biosciences tumbles on $250 mln share sale
Brief: Arcus Biosciences Announces Pricing Of $250 Million Public Offering Of Common Stock
Arcus Biosciences drops after starting stock offering